Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...
Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease. At the ...
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to ...
With an infrastructure in place to market its lone commercial product Ruconest, it made sense in 2019 for Pharming Group to scoop up another rare disease candidate in the same arena. Four years later, ...
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...
Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta ...
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of ...
A pharming attack tries to redirect a website’s traffic to a fake website controlled by the attacker, usually for the purpose of collecting sensitive information from victims or installing malware on ...
First came phishing scams, in which con artists hooked unwary internet users one by one into compromising their personal data. Now the latest cyberswindle, pharming, threatens to reel in entire ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback